Radiation Therapy in Treating Women Who Have Undergone Surgery for Early-Stage Invasive Breast Cancer

• ClinicalTrials.gov Identifier: NCT00005957
• Recruitment Status: Completed
• First Posted: January 27, 2003
• Results First Posted: June 15, 2016
• Last Update Posted: August 21, 2023
• Sponsor: NCIC Clinical Trials Group
• Collaborators: National Cancer Institute (NCI); NSABP Foundation Inc; Radiation Therapy Oncology Group; SWOG Cancer Research Network; Trans Tasman Radiation Oncology Group; North Central Cancer Treatment Group
• Information provided by (Responsible Party): Canadian Cancer Trials Group ( NCIC Clinical Trials Group )

Tracking Information

• First Submitted Date: July 5, 2000
• First Posted Date: January 27, 2003
• Results First Submitted Date: April 5, 2016
• Results First Posted Date: June 15, 2016
• Last Update Posted Date: August 21, 2023
• Actual Study Start Date: March 9, 2000
• Actual Primary Completion Date: November 20, 2014 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: May 9, 2016)

Overall Survival [ Time Frame: 10 years ]

Duration of study

• Original Primary Outcome Measures: Not Provided

Current Secondary Outcome Measures (submitted: May 9, 2016)

Disease-free Survival [ Time Frame: 10 years ]

Disease-free survival (including locoregional and distant disease)

• Original Secondary Outcome Measures: Not Provided
• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Radiation Therapy in Treating Women Who Have Undergone Surgery for Early-Stage Invasive Breast Cancer
• Official Title: A Phase III Study of Regional Radiation Therapy in Early Breast Cancer

Brief Summary

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Radiation to the tumor site and surrounding area may kill more tumor cells. It is not yet known if radiation therapy to the breast alone following surgery is more effective than radiation therapy to the breast plus surrounding tissue in treating invasive breast cancer.

PURPOSE: This randomized phase III trial is studying radiation therapy to the breast alone to see how well it works compared to radiation therapy to the breast plus surrounding tissue in treating women who have undergone surgery for early-stage invasive breast cancer.

Detailed Description

OBJECTIVES:

• Compare the overall survival, disease-free survival, isolated local regional disease-free survival, and distant disease-free survival in women with previously resected, early stage, invasive breast cancer treated with breast radiotherapy with or without regional radiotherapy.
• Compare the toxic effects of these regimens in these patients.
• Compare the quality of life of patients (in certain participating centers) treated with these regimens.
• Compare the cosmetic outcomes in patients (in certain participating centers) treated with these regimens.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to number of positive nodes (0 vs 1-3 vs more than 3), number of axillary nodes removed (<10, > or equal to 10); type of chemotherapy (anthracycline containing vs other vs none), hormonal therapy (yes vs no), number of axillary lymph nodes excised*, and participating center. Patients are randomized to one of two treatment arms.

NOTE: * Patients with a negative sentinel node dissection with or without an axillary dissection will be stratified according to the total number of nodes removed

• Arm I: Patients undergo standard breast radiotherapy alone 5 days a week for 5 weeks in the absence of disease progression or unacceptable toxicity.
• Arm II: Patients undergo breast and regional radiotherapy 5 days a week for 5 weeks in the absence of disease progression or unacceptable toxicity.

Radiotherapy in both arms begins as soon as possible after randomization. Radiotherapy must begin within 8 weeks after completion of adjuvant IV chemotherapy, unless radiotherapy is administered concurrently with chemotherapy (i.e., cyclophosphamide, methotrexate, and fluorouracil [CMF]), or within 16 weeks after the last breast surgery for patients treated with hormonal therapy alone.

Quality of life is assessed (in patients in certain participating centers) within 2 weeks prior to randomization, during the last week of radiotherapy, at 3 and 9 months after completion of radiotherapy, and then annually until first distant disease recurrence.

Cosmetic outcome is assessed (in patients in certain participating centers) within 2 weeks prior to randomization, and then at 3 and 5 years after completion of radiotherapy or until first distant disease recurrence.

Patients are followed at 3, 6, and 9 months, every 6 months for 2 years, and then annually thereafter.

PROJECTED ACCRUAL: Approximately 1,822 patients will be accrued for this study within approximately 4 years.

• Study Type: Interventional
• Study Phase: Not Applicable
• Study Design: Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: None (Open Label); Primary Purpose: Treatment
• Condition: Breast Cancer

Intervention

• Radiation: Standard Breast Irradiation
  Standard Breast Irradiation - A dose of 5000 cGy in 25 fractions at a rate of 200 cGy per day, 5 days a week for 5 weeks will be prescribed to the standard tangent fields.
• Radiation: Breast Radiation plus Regional Radiation
  Breast Radiation plus Regional Radiation - A dose of 5000 cGy in 25 fractions at a rate of 200 cGy per day, 5 days a week for 5 weeks will be prescribed to the modified wide tangent fields.

Study Arms

• Active Comparator: Standard Breast Irradiation
  Intervention: Radiation: Standard Breast Irradiation
• Experimental: Breast Radiation plus regional radiation
  regional radiation therapy (to the ipsilateral supraclavicular, axillary and internal mammary nodes)
  Intervention: Radiation: Breast Radiation plus Regional Radiation

Publications *

• Whelan TJ, Olivotto IA, Parulekar WR, Ackerman I, Chua BH, Nabid A, Vallis KA, White JR, Rousseau P, Fortin A, Pierce LJ, Manchul L, Chafe S, Nolan MC, Craighead P, Bowen J, McCready DR, Pritchard KI, Gelmon K, Murray Y, Chapman JA, Chen BE, Levine MN; MA.20 Study Investigators. Regional Nodal Irradiation in Early-Stage Breast Cancer. N Engl J Med. 2015 Jul 23;373(4):307-16. doi: 10.1056/NEJMoa1415340.
• Gross JP, Whelan TJ, Parulekar WR, Chen BE, Rademaker AW, Helenowski IB, Donnelly ED, Strauss JB. Development and Validation of a Nomogram to Predict Lymphedema After Axillary Surgery and Radiation Therapy in Women With Breast Cancer From the NCIC CTG MA.20 Randomized Trial. Int J Radiat Oncol Biol Phys. 2019 Sep 1;105(1):165-173. doi: 10.1016/j.ijrobp.2019.05.002. Epub 2019 May 11.

Recruitment Information

• Recruitment Status: Completed
• Actual Enrollment (submitted: June 20, 2013): 1832
• Original Enrollment: Not Provided
• Actual Study Completion Date: April 19, 2017
• Actual Primary Completion Date: November 20, 2014 (Final data collection date for primary outcome measure)

Eligibility Criteria

DISEASE CHARACTERISTICS:

• Histologically proven invasive carcinoma of the breast

  • No evidence of T4, N2-3, or M1 disease prior to surgery
  • Node positive or high-risk node negative

• Prior breast-conserving therapy (BCT) (e.g., lumpectomy, partial mastectomy, or segmental mastectomy) and axillary node dissection or sentinel node biopsy required and must be a candidate for breast radiotherapy after BCT

  • Normally patients should have microscopically clear resection margins and those with positive margins should undergo reexcision
  • Patients with microscopically focally positive margins (defined as no greater than 3 times high power fields) are candidates for breast radiotherapy plus a boost to the lumpectomy site

  • Patients with prior sentinel node dissection eligible if node negative, but still meet high-risk criteria

    • If node positive, then a level I and II axillary dissection must be performed
  • No evidence of residual disease in axilla after dissection
• Must be treated with currently accepted adjuvant systemic chemotherapy and/or hormonal therapy

• High risk of regional and systemic recurrence due to one of the following:

  • Pathologically positive axillary lymph nodes

  • Pathologically negative axillary lymph nodes with one of the following:

    • Primary tumor greater than 5 cm

    • Primary tumor greater than 2 cm and less than 10 axillary lymph nodes excised and one of the following:

      • Estrogen receptor negative
      • Skarf-Bloom-Richardson grade 3
      • Lymphovascular invasion

• Hormone receptor status:

  • Estrogen and progesterone receptor status known

PATIENT CHARACTERISTICS:

Age:

• 16 and over

Sex:

• Female

Menopausal status:

• Premenopausal or postmenopausal

Performance status:

• ECOG 0-2

Life expectancy:

• At least 5 years

Hematopoietic:

• Not specified

Hepatic:

• SGOT and/or SGPT no greater than 3 times upper limit of normal (ULN)*
• Alkaline phosphatase no greater than 3 times ULN* NOTE: * Patients with laboratory values greater than 3 times ULN may still be eligible if no metastatic disease by imaging examinations

Renal:

• No serious nonmalignant renal disease

Cardiovascular:

• No serious nonmalignant cardiovascular disease

Pulmonary:

• No serious nonmalignant pulmonary disease

Other:

• Not pregnant or nursing
• Fertile patients must use effective contraception
• No other serious nonmalignant disease (e.g., systemic lupus erythematosus or scleroderma) that would preclude definitive surgery or radiotherapy

• No other malignancy except:

  • Nonmelanomatous skin cancer
  • Carcinoma in situ of the cervix or endometrium
  • Contralateral noninvasive breast cancer (unless prior radiotherapy to the contralateral breast)
  • Invasive carcinoma of the cervix, endometrium, colon, thyroid, or melanoma that was curatively treated at least 5 years prior to study participation
• No psychiatric or addictive disorder that would preclude informed consent or study compliance

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• Not specified

Chemotherapy:

• See Disease Characteristics
• Concurrent standard adjuvant chemotherapy allowed

Endocrine therapy:

• See Disease Characteristics
• Concurrent standard adjuvant hormonal therapy allowed

Radiotherapy:

• See Disease Characteristics

Surgery:

• See Disease Characteristics

Sex/Gender

• Sexes Eligible for Study: Female

• Ages: 16 Years to 120 Years (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: Canada
• Removed Location Countries: United States

Administrative Information

• NCT Number: NCT00005957
• Other Study ID Numbers: MA20; CAN-NCIC-MA20; NSABP-CAN-NCIC-MA20 ( Other Identifier: NSABP ); NCCTG-CAN-NCIC-MA20 ( Other Identifier: NCCTG ); RTOG-CAN-NCIC-MA20 ( Other Identifier: RTOG ); SWOG-CAN-NCIC-MA20 ( Other Identifier: SWOG ); TROG-CAN-NCIC-MA20 ( Other Identifier: TROG ); CDR0000067938 ( Other Identifier: PDQ )
• Has Data Monitoring Committee: Yes

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

IPD Sharing Statement

• Plan to Share IPD: No

• Current Responsible Party: Canadian Cancer Trials Group ( NCIC Clinical Trials Group )
• Original Responsible Party: Not Provided
• Current Study Sponsor: NCIC Clinical Trials Group
• Original Study Sponsor: Canadian Cancer Trials Group

Collaborators

• National Cancer Institute (NCI)
• NSABP Foundation Inc
• Radiation Therapy Oncology Group
• SWOG Cancer Research Network
• Trans Tasman Radiation Oncology Group
• North Central Cancer Treatment Group

Investigators

• Study Chair: Timothy J. Whelan, MD; Margaret and Charles Juravinski Cancer Centre
• Study Chair: David S. Parda; Allegheny Cancer Center at Allegheny General Hospital
• Study Chair: Julia R. White, MD; Medical College of Wisconsin
• Study Chair: Lori J. Pierce, MD; University of Michigan Rogel Cancer Center
• Study Chair: Boon Chua, MD; Peter MacCallum Cancer Centre, Australia
• Study Chair: Laura A. Vallow, MD; Mayo Clinic

• PRS Account: Canadian Cancer Trials Group
• Verification Date: March 2020